The study demonstrates considerable antigenic variation in coxsackievirus B3 strains using monoclonal antibody profiling.
Answers are grounded in this paper and cite their sources.
Antigenic variation in CoxB3 may limit monoclonal antibody utility; hypothesis-generating for human strain surveillance and vaccine design.
All the 16 mouse monoclonal antibodies (McAbs) raised against Nancy strain of coxsackievirus B3, CoxB3(N), were type 3-specific. The reactivity of CoxB3(N) to this McAb panel during the serial passages showed a variation. Three field isolates of CoxB3, all neutralizable with the reference Anti-CoxB3 hyperimmune serum, were checked for the reactivities with the McAb panel. The isolates from the patients in Fujiang reacted with 12 McAbs and variably with the remaining four McAbs. On the basis of the reactivities with different virus strains, the McAbs were found to fall into four groups possibly corresponding to at least four epitopes. A considerable antigenic variation of CoxB3 was thus suggested.
No takes yet. Share an insight, caveat, or question.
Hu et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: